Evidence map›Paper›PMID 28609680›Full record

ArticleNeoplasia (New York, N.Y.)2017

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).

Madhura Joglekar-Javadekar, Steven Van Laere, Michael Bourne, Manal Moalwi, Pascal Finetti, Peter B Vermeulen, Daniel Birnbaum, Luc Y Dirix, Naoto Ueno, Monique Carter and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. PNME - A gene-gene parallel network module extraction method.Journal, genetic engineering & biotechnology · 2018
    Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Madhura Joglekar-JavadekarThe Laboratory for Cytoskeletal Physiology, Department of Biological Sciences, The University of Delaware, Newark, DE; The Center for Translational Cancer Research, The University of Delaware, Newark, DE.
Steven Van LaereCenter for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Michael BourneThe Laboratory for Cytoskeletal Physiology, Department of Biological Sciences, The University of Delaware, Newark, DE; The Center for Translational Cancer Research, The University of Delaware, Newark, DE.
Manal MoalwiThe Laboratory for Cytoskeletal Physiology, Department of Biological Sciences, The University of Delaware, Newark, DE; The Center for Translational Cancer Research, The University of Delaware, Newark, DE.
Pascal FinettiDepartment of Molecular Oncology, Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Institut Paoli-Calmettes (IPC), Marseille, France.
Peter B VermeulenCenter for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Daniel BirnbaumDepartment of Molecular Oncology, Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Institut Paoli-Calmettes (IPC), Marseille, France.
Luc Y DirixCenter for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Naoto UenoBreast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Monique CarterAROG Pharmaceuticals LLC, Dallas, TX.
Justin RainsAROG Pharmaceuticals LLC, Dallas, TX.
Abhijit RamachandranAROG Pharmaceuticals LLC, Dallas, TX.
Francois BertucciDepartment of Molecular Oncology, Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Institut Paoli-Calmettes (IPC), Marseille, France.
Kenneth L van GolenThe Laboratory for Cytoskeletal Physiology, Department of Biological Sciences, The University of Delaware, Newark, DE; The Center for Translational Cancer Research, The University of Delaware, Newark, DE; The Helen F. Graham Cancer Center, Newark, DE. Electronic address: klvg@udel.edu.
University of Delaware · USArog Pharmaceuticals (United States) · USUniversity of Antwerp · BECentre de Recherche en Cancérologie de Marseille · FRCentre National de la Recherche Scientifique · FRThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInflammatory breast cancer (IBC) is arguably the deadliest form of breast cancer due to its rapid onset and highly invasive nature. IBC carries 5- and 10-year disease-free survival rates of ~45% and <20%, respectively. Multiple studies demonstrate that in comparison with conventional breast cancer, IBC has a unique molecular identity. Here, we have identified platelet-derived growth factor receptor alpha (PDGFRA) as being uniquely expressed and active in IBC patient tumor cells. EXPERIMENTAL

designHere we focus on characterizing and targeting PDGFRA in IBC. Using gene expression, we analyzed IBC patient samples and compared them with non-IBC patient samples. Further, using IBC cells in culture, we determined the effect of small molecules inhibitors in both in vitro and in vivo assays.

resultsIn IBC patients, we show more frequent PDGFRA activation signature than non-IBC samples. In addition, the PDGFRA activation signature is associated with shorter metastasis-free survival in both uni- and multivariate analyses. We also demonstrate that IBC cells express active PDGFRA. Finally, we show that PDGFRA targeting by crenolanib (CP-868-596), but not imatinib (STI571), two small molecule inhibitors, interferes with IBC cell growth and emboli formation in vitro and tumor growth in vivo.

conclusionsOur data suggest that PDGFRA may be a promising target for therapy in IBC.

Indexed as

AdultAgedAnimalsAntineoplastic AgentsBenzimidazolesCell Line, TumorCell SurvivalDisease Models, AnimalFemaleFollow-Up StudiesGene ExpressionHumansInflammatory Breast NeoplasmsMiceMiddle AgedMutationAntineoplastic AgentsBenzimidazolescrenolanibPiperidinesPlatelet-Derived Growth FactorReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID28609680
PMCPMC5470553
OpenAlexW2623655675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.